Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes and obesity.

Our history spans a century and it all began with two small Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. After hearing of the discovery of insulin in 1921, Danish Nobel laureate August Krogh and …

Overview of Novo Nordisk pharmaceutical products within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.

At Novo Nordisk, you will have the opportunity to build a life-changing career in a global business environment. Join us and make a difference.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in serious chronic disease treatment.

Do you need to get in touch with us? See your options here. Reach out to your local Novo Nordisk office or call our corporate headquarters. Tel: +45 4444 8888, Novo Allé, 2880 Bagsvaerd, Denmark.

2025年1月8日 · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

2020年12月16日 · Novo Nordisk Executive Management and other members of senior management provided a full review of our strategy, operations and financial targets. Download the presentations and watch the webcast

In some cases, healthcare professionals and patients can visit local Novo Nordisk websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources.